EMTAF-B tablets are an antiviral prescription medicine containing 25 mg of tenofovir alafenamide .  They are primarily used to treat chronic Hepatitis –B virus (HBV)  infection in adults and adolescent and can also form part of combination regimes for managing HIV infections. It plays a role in disease management by managing chronic hepatitis –B virus (HBV) infections and assisting in combination therapies for HIV. It works by stopping viral replication , which lowers viral load , reduces liver inflammation and prevents the severe long-term damage.

WHAT ARE EMTAF-B TABLETS  ?

EMTAF-B tablets are classified as antiviral medications, specifically belonging to the class of nucleotide reverse transcriptase (NtRTIs) or nucleotide analogs. They contain the active ingredient tenofovir alafenamide (25 mg).

Key classification:

• Therapeutic category: Antiviral agent
• Pharmacological class: Nucleotide analogue reverse transcriptase inhibitor (NtRI).
• Active ingredient: Tenofovir alafenamide (25 mg)
• Mechanism of Action: Tenofovir alafenamide enters target cells where it is hydrolyzed and transformed into its active form, tenofovir diphosphate (TFV-DP). The active TFV-DP compares with natural nucleotides to inhibit viral DNA polymerase . once incorporated into the DNA Chain, it stops further DNA synthesis , preventing the virus from multiplying and lowering the viral load.
• Medicine is intended to be used: They work by lowering the amount of virus in the body and slowing liver damage , and they may also be used alongside other drugs to treat HIV. Take the dosage exactly according to once exact prescription and scheduled . Take the tablet with food to help the body absorb the medicine properly. Regular blood-test are required to check the liver and kidney function while on this therapy.

WHAT ARE THE USES OF EMTAF-B TABLETS?

Uses of EMTAF-B tablets are:

1)Approved medical indications

EMATAF-B tablets contain tenofovir alafenamide (25 MG) and are officially approved for the treatment of chronic hepatitis –B virus (HBV) infection in adults and adolescent aged 12 years and older. They work by lowering the viral load and reducing liver damaged. Some of the approved medical uses are:

• Chronic Hepatitis B: managing long-term HBV infection in patients with compensated liver disease
• HIV management : occasionally used as part of a combination regime with other antiretroviral for HIV-1 infection .

2)Role in managing the underlying conditions

EMTABF –B tablets manage chronic hepatitis B virus (HBV) and HIV infections by stopping the virus from multiplying in the body.it contains Tenofovir alafenamide, an antiviral medication . it changes into its active form inside cells to block viral DNA  production. It also lowers the viral load, which is the amount of virus present in the blood. It controls long-term liver infections , reduces liver inflammation, and lowers the risk of severe damage like scarring or cancer. It is used alongside other medicines to treat human immunodeficiency virus . it also target infected cells effectively while remaining gentler on bones and kidneys compared to older treatments.

3)Used alone or in combination with other medicines , when appropriate

EMTAFB tablets contain tenofovir alafenamide (25 mg) and are primarily used to treat chronic hepatitis B virus (HBV) infection, and when appropriate , they are combined with other antiretroviral medicines to manage HIV-1  infection . it slows the replication of hepatitis B virus, reducing the viral load in the blood and lowering the risk of  severe liver damage like cirrhosis.

• When treating HIV, it is always used alongside other antireotroviral medications to prevent viral resistance and treatment failure.

WHAT ARE THE BENEFITS OF EMTAF-B TABLETS?

Benefits of EMTAF –B tablets are:

• THERAPEUTIC BENEFITS
• Reduces Viral Activity

Stops the virus from multiplying , which lowers the amount of virus In the blood to very low to undetectable levels.

• Protects liver health

Decreases liver inflammation and lower the risk of severe damage,such as scarring or liver failure.

• Supports immunity

Helps preserve the immune system and delays disease progression when managing HIV or viral co-infections.

• Kidney and Bone safety

Uses a targeted design that delivers medicine directly to liver cells, reducing harmful exposure to one kidneys and bones compared to older antiviral treatments.

• Role in controlling the underlying conditions

EMTAF –B  controls chronic hepatitis –B and HIV infections by stopping the virus from making copies of itself , which lowers the amount of virus in the blood and protects organ health.

• For Hepatitis B: it decreases liver swelling and lowers the chance of dangerous scarring,known as cirrhosis or liver cancer.
• For HIV: it tightens the work on one immune system so it can stay strong and fight off other sickness
• Targeted safety : it moves directly into the target cells, which keeps the bones and kidneys safer than other antiviral drugs.

• Expected treatment outcomes

EMTAF –B is expected treatment outcomes include effective viral suppression, reduced liver inflammation and a lower risk of long-term liver damage. Some of the expected treatment outcomes of EMTAF-B are:

• Viral suppression: The medication successfully lowers the amount of the hepatitis B virus (HBV) in ones blood to undetectable or very low levels.
• Reduced inflammation: it decreases active liver inflammation and helps improves overall liver function test over time.
• Lower Disease Progression: long-term use minimizes the risk of severe complications, such as liver scarring or liver cancer
• High barrier to resistance: clinical studies show a very low rate of the virus developing resistance to the medication during extended treatment.

Importance of adherence to prescribed therapy

Adherence strictly to prescribed therapy is essential to suppress the virus, prevent drug resistance, and protect the liver. Adherence matters to the following:

• Sustained viral suppression: taking ones dose daily keeps steady drug levels in one’s body to stop the hepatitis B virus (HBV) from multiplying.
• Preventing resistance: missing doses allows the virus to adapt, creating drug-resistant strains that make future treatment fail.
• Avoiding liver flares: stopping treatment suddenly can trigger severe spikes in liver inflammation, known as hepatic flares or liver decomposition .
• Lowering long-term risks: consistent use reduces the chances of developing severe complications like cirrhosis or liver cancer .

CONCLUSION

EMTAF-B tablets are concluded to be an effective, well-tolerated treatment for chronic Hepatitis B virus (HBV) infection, offering a safer renal profile than older formulations. The 25 mg tablets are used for long-term management to suppress viral replication with lower synthetic plasma concentration compared to TDF.

FREQUENTLY ASKED QUESTIONS (FAQs):

                      QUESTION: WHAT IS                      EMTAF-B IS USED FOR?

EMTAF-B tablets are primarily used to treat chronic hepatitis B virus (HBV) infection and as part of combination therapy for HIV-I infection.

QUESTION: HOW SHOULD EMTAF-B TABLETS BE TAKEN?

EMTAF-B tablets , which contains tenofovir,  alafenamide, are generally taken orally , usually with food, to ensure proper absorption. Taking the medicine at the same time each day helps maintain consistent levels in the body.

QUESTION: WHAT ARE THE ACTIVE INGREDIENTS IN EMTAF-B ?

EMTAF-B contain tenofovir alafenamide (25 mg) as their single active ingredient .

REFRENCES:

1)

https://www.1mg.com/drugs/emtaf-b-tablet-485638?wpsrc=Google+Organic+Search

2)https://www.truemeds.in/medicine/emtaf-b-25-mg-tablet-30-tm-tacr1-013301